Committed to developing a device that will eradicate maternal death caused by postpartum hemorrhage (PPH)

InPress Technologies is a medical device company working toward a solution to postpartum hemorrhage (PPH,) the number one cause of maternal death. Our single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. We are devoted to improving the lives of women around the world.

InPress Technologies was a company-in-residence at the Fogarty Institute for Innovation (FII) in Mountain View CA. FII is a catalyst for medical device innovation and provides intellectual and physical resources to early-stage innovators whose ideas have significant technical merit and a high potential of improving the lives of people around the world. In July 2014, InPress was the recipient of the Lefteroff Innovator Award, which directly funds projects for promising new innovators working on pre-screened medical ideas. The Lefteroff Fund was developed to recognize Tracy Lefteroff for his legacy of commitment and dedication to entrepreneurship, investment and innovation in the life sciences.

InPress Technologies traces its history to Cal Poly (California Polytechnic State University) in San Luis Obispo, CA, where two biomedical engineers conceived our innovative approach to postpartum hemorrhage. Over the next couple of years, the team received extensive support from Innovation Quest, the San Luis Obispo HotHouse Accelerator, and the Cal Poly Small Business Development Center. The encouragement of these organizations helped the founders synthesize their idea further, conduct initial analyses, and outline a path to bring our first product to market.

Partners and Mentors

  • Fogarty Institute for Innovation Company in Residence
  • SLO HotHouse Incubator Company
  • The Cal Poly Center for Innovation and Entrepreneurship

The InPress Device

Postpartum hemorrhage (PPH) is excessive bleeding in a mother after childbirth. PPH is the leading cause of perinatal maternal death around the world—it is estimated that one woman dies from PPH every four minutes.

Clinically, 80% of the instances of PPH are caused by the failure of the uterus to contract after childbirth. This condition, known as uterine atony, leaves the blood vessels fully dilated and brings about unobstructed bleeding.

The investigational InPress Postpartum Hemorrhage Intrauterine Device is designed to facilitate the body’s natural mechanism for control of postpartum hemorrhage, without pharmaceuticals, hysterectomy, or other invasive surgical procedures. As opposed to merely treating the symptoms of PPH, the investigational InPress Device is designed to stop bleeding by causing uterine collapse with tamponade and stimulating uterine contractions allowing the uterus to return to the right postpartum size.

Our vision is to make the InPress Device affordable and accessible in developed and developing countries thus helping save the lives of women around the world.

CAUTION: Investigational Device. Limited by U.S. law to investigational use.

  • “The InPress technology has the potential to change the way postpartum hemorrhage is treated and save many lives.”
    Suellen Miller, Director of Safe Motherhood Program
  • “The InPress Device is uniquely designed to work in concert with normal uterine mechanisms to stop PPH.”
    Jan Segnitz, MD, OB/GYN, InPress Medical Advisor

Vision. Inspiration. Experience. Impact.


InPress Technologies is excited to share that the results of the feasibility clinical study of the InPress Device were supportive of moving forward with a pivotal clinical trial of the device.

Inpress is ISO 13485 Certified

InPress Technologies has developed the necessary engineering controls to ensure consistent product quality. The InPress quality management system has earned the company this internationally recognized certification.

Recent Press Coverage

Winner of the Most Innovative Field-tested Prototype at the Stanford-America India Foundation Symposium on Maternal and Child Health, October 14, 2016

“Control of Postpartum Hemorrhage Using Vacuum-Induced Uterine Tamponade” in Obstetrics & Gynaecology (Green Journal), Global Health: Procedures and Instruments Wolters Kluwer Health, Inc., Vol. 128, No. 1, July 2016

“InPress Technologies: Halting Postpartum Hemorrhage” in Pharma & Medtech Business Intelligence, July 14, 2015

“A Life-Saving Startup” in Cal Poly Business Magazine, July 7, 2015

“InPress Technologies initial study supports device’s treatment for PPH” in Medical Device Daily, April 24, 2015

“SLO-based company develops device to save hemorrhaging mothers’ lives” in The Tribune, San Luis Obispo, January 5, 2015